Showcases Stock ranks Forex

Iveric Bio Inc (ISEE)
13.25  0.44 (3.43%) 08-08 16:00
Open: 13 Pre. Close: 12.81
High: 13.37 Low: 12.81
Volume: 2,323,367 Market Cap: 1,543M
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 13.378 - 13.418 13.418 - 13.462
Low: 12.692 - 12.739 12.739 - 12.792
Close: 13.164 - 13.238 13.238 - 13.32
Stock Technical Analysis
Target: Six months: 15.62
One year: 18.24
Support: Support1: 11.31
Support2: 10.04
Resistance: Resistance1: 13.37
Resistance2: 15.62
Pivot: 11.44
Moving Averages: MA(5): 12.13
MA(20): 11.48
MA(100): 12.49
MA(250): 13.96
MACD: MACD(12,26): 0.38
Signal(12,26,9): 0.18
%K %D: %K(14,3): 89.34
%D(3): 69.98
RSI: RSI(14): 68.91
52-Week: High: 19.345
Low: 8.37
Change(%): 47.2
Average Vol(K): 3-Month: 2054
10-Days: 2010
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ ISEE ] has closed above the upper band by 7.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 7.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Sun, 07 Aug 2022
IVERIC bio, Inc. (NASDAQ:ISEE) SVP Sells $138060.00 in Stock - Defense World

Thu, 04 Aug 2022
IVERIC bio, Inc. (NASDAQ:ISEE) Shares Acquired by Arizona State Retirement System - Defense World

Thu, 04 Aug 2022
IVERIC Bio Inc (NASDAQ: ISEE) Announces License Agreement With DelSiTech Ltd For Zimura - BP Journal

Wed, 03 Aug 2022
Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022 - Bluefield Daily Telegraph

Wed, 03 Aug 2022
IVERIC bio (NASDAQ:ISEE) Receives New Coverage from Analysts at UBS Group - Defense World

Tue, 02 Aug 2022
IVERIC bio (NASDAQ:ISEE) Now Covered by Analysts at UBS Group - MarketBeat

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 118.08
Shares Float (M) 97.07
% Held by Insiders 0.59
% Held by Institutions 110.17
Shares Short (K) 7450
Shares Short Prior Month (K) 8770
Stock Financials
EPS -1.130
Book Value (p.s.) 2.510
Profit Margin
Operating Margin
Return on Assets (ttm) -36.6
Return on Equity (ttm) -65.4
Qtrly Rev. Growth
Gross Profit (p.s.) -0.720
Sales Per Share
EBITDA (p.s.) -1.203
Qtrly Earnings Growth
Operating Cash Flow (M) -122.07
Levered Free Cash Flow (M) -71.43
Stock Valuation
PE Ratio -11.73
PEG Ratio
Price to Book value 5.28
Price to Sales
Price to Cash Flow -12.82
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android